scout

Authors

Kimberly L. Blackwell, MD, Duke
Kimberly L. Blackwell, MD, Duke Cancer Institute
Kimberly L. Blackwell, MD, Duke University Medical Center
Kimberly L. Blackwell, MD, Duke University School of Medicine
Klaus Podar, MD, PhD
Latest Article

Updates on Multiple Myeloma Diagnosis and Treatment Strategies

Progress in our understanding of multiple myeloma pathogenesis has led to the identification of new therapeutic targets.

Komal Jhaveri, MD, FACP, Memorial Sloan Kettering Cancer Center
Krisha J. Howell, MD
Latest Article

Fresh Approaches to RT Improve Outcomes in Retroperitoneal Sarcoma

Each year, 10% to 15% of patients with soft-tissue carcinomas receive a diagnosis of rare retroperitoneal sarcoma (RPS), an aggressive disease that typically recurs in 26% of cases and has a 47% to 67% five-year overall survival rate. New radiation therapies hold potential to decrease treatment time and provide local control of RPS.

Krishna V. Komanduri, MD, Sylvester Comprehensive Cancer Center
Kristen Ganjoo, MD, Stanford University Medical Center
Kristi Rosa
Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Latest Article

Frontline Retifanlimab Approaches EU Approval for Advanced Squamous Cell Carcinoma of the Anal Canal

EMA CHMP recommends first-line retifanlimab plus carboplatin/paclitaxel for advanced anal cancer, backed by phase 3 P0D1UM-303 data.

Kristin Anderson, PhD
Latest Article

Paying It Forward in Oncology: A Journey From Patient to Investigator

Kristin Anderson, PhD, shares her journey from patient to investigator.

Kristin Higgins, MD, Emory Healthcare
Kristin Rojas, MD
Latest Article

Turning the Tide on Opioid Prescribing Practices

As evidence grows that opioids may potentially worsen oncologic outcomes, surgeons and oncology providers must take an active role in addressing the opioid crisis by adopting similar protocols that decrease the quantity of narcotics available for diversion while ensuring safe patient care.

Krithika Subramanian, PhD
Latest Article

TILs Show Growing Potential as Novel Immunotherapy

Although checkpoint-blocking antibodies dominate the anticancer immunotherapy field today, researchers are increasingly exploring the potential to leverage growing knowledge about tumor-infiltrating lymphocytes to develop new drugs.

Krystal Knapp
Latest Article

The Great Biomarker Chase: Promise & Pitfalls Along the Path to Personalized Care

Biomarkers offer great potential for improving management of cancer at every point from screening and detection, to diagnosis, staging, prognosis, and the assessment of treatment response.

Krystal Knapp, Ben Leach
Latest Article

The Year's New Drugs: Integrating Advances of 2011 Into Treatment Plans

The FDA approved more new oncology drugs in 2011 than it has in a single year in more than a decade, thanks in part to priority review and streamlined evaluation procedures. While this is good news for patients, oncology and hematology specialists must tackle the challenges posed by integrating new therapies into treatment plans. Leading specialists give their perspectives on key issues.

Kunle Odunsi, MD, PhD, FRCOG, FACOG
Latest Article

Proposed Trial Would Be First Ever for Novel Two-Pronged Immunotherapy Strategy

Roswell Park Cancer Institute is taking the final steps toward what we believe would be the first-ever clinical trial combining two novel and highly promising techniques: adoptive cellular therapy utilizing re-engineered mature T cells and re-engineered adult hematopoietic stem cells.

Kuo Bianchini Tong, MS
Latest Article

Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer

Breast cancers with similar clinicopathologic characteristics may have strikingly different outcomes.

Kurt Ullman
Latest Article

Practice Benchmark Report Offers Hope for Survival of Independent Oncology Practices

The narrowing difference between operating cost and total medical revenue has eased, buying some time for practices to adjust their business models and perhaps survive.

Lalan Wilfong, MD
Latest Article

Dr Wilfong on the Potential Use of AI Prediction Models to Improve Palliative Care in Oncology

Lalan Wilfong, MD, expands on the value of AI prediction models for consensus on patient prognosis and better end-of-life care in oncology.

Lane Rosen
Latest Article

Reduce Costs By Using Less Radiotherapy

Radiation therapy remains fertile for continued technological innovation that can improve patient outcomes, but of the newest technologies may be practical for only the largest institutions.

Larry Kestin MD
Latest Article

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Laura Bruck
Latest Article

A Life Redirected: Pursuing a Nursing Career After Osteosarcoma

In the summer of 2010, 20-year-old physical therapy student Hannah Komai was diagnosed with low-grade osteosarcoma after an incisional biopsy.

Laura Jones
Laura M. Kulik, MD, Northwestern University Feinberg School of Medicine
Laura M. Perry, BS
Latest Article

Informed Patients Are More Likely to Choose Palliative Care

Research from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.

Laura Panjwani
Latest Article

Expert Discusses Promise of Quizartinib in AML

Mark Levis, MD, PhD, highlights the promise and potential challenges of the FLT3-inhibitor quizartinib in acute myeloid leukemia.

Laura Yarbro, PharmD
Latest Article

Denosumab: A Review of Its Pharmacology and Clinical Implications

It is estimated that approximately 80% of all patients with diagnoses of breast cancer, prostate cancer, or multiple myeloma will develop bone metastases at some time during the course of their disease.

Laurel A. Menapace, MD
Latest Article

Challenging Case Teaches Oncology Fellow the Power of Hope

Advanced esophageal cancer is a highly lethal malignancy and often spreads despite aggressive therapy.

Lauren C. Harshman, MD1
Latest Article

The Therapeutic Landscape of Metastatic Renal Cell Carcinoma in 2012

In the last seven years, since the introduction of the targeted therapies, remarkable progress has transpired that has transformed the therapeutic landscape for metastatic renal cell carcinoma.